Related Experiment Video

Updated: Aug 7, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

[Effect of apolipoprotein E phenotypes on the response to dietary treatment of children with hypercholesterolemia]

M J Ramo Herrero1, L A Moreno Aznar, A Sarría Chueca

  • 1Departamento de Bioquímica, Facultad de Medicina, Universidad de Zaragoza.

Anales Espanoles De Pediatria
|November 27, 1999
PubMed

Insights

Apolipoprotein E (apo E) phenotypes did not significantly impact dietary intervention response in children with hypercholesterolemia. Further research into familial and genetic factors is needed to understand response variability.

Area of Science:

  • Biochemistry
  • Genetics
  • Pediatrics

Background:

  • Hypercholesterolemia in children requires effective dietary interventions.
  • Apolipoprotein E (apo E) phenotypes are known to influence lipid metabolism.
  • The role of apo E phenotypes in pediatric hypercholesterolemia response to diet is not fully understood.

Purpose of the Study:

  • To investigate the effect of apo E phenotypes on serum lipoprotein levels in children with hypercholesterolemia undergoing dietary intervention.

Main Methods:

  • Seventy-six children with high cholesterol (>200 mg/dL) were enrolled.
  • Dietary recommendations focused on low total and saturated fat intake (30% and 10% of energy).
  • Lipoprotein profiles were assessed at diagnosis and after 6 months of dietary therapy.

Main Results:

  • Children with apo E phenotype E3/E4 showed significant reductions in total cholesterol, LDL-cholesterol, and triglycerides after 6 months.
  • No significant differences in lipoprotein changes were observed between different apo E phenotype groups when comparing absolute and percentage differences.

Conclusions:

  • Apo E phenotypes do not appear to determine the response to low-fat, low-cholesterol diets in this cohort of hypercholesterolemic children.
  • Investigating other familial and genetic factors may elucidate the variability in dietary intervention response.
Abstract

More Related Videos

Quantification of Atherosclerosis in Mice06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...